Estimating the public health importance of the CYD-tetravalent dengue vaccine: Vaccine preventable disease incidence and numbers needed to vaccinate

Vaccine

Volumn 34, Issue 20, 2016, Pages 2397-2401

  Gessner, Bradford D ^a   Wilder Smith, Annelies ^b,c  

^a Agence de Médecine Préventive AMP   (France)

^b NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

CYD TDV; Dengue; Dengue vaccine; Number needed to vaccinate; Vaccine effectiveness; Vaccine efficacy; Vaccine preventable disease incidence

Indexed keywords

DENGUE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; PNEUMOCOCCUS VACCINE; ROTAVIRUS VACCINE; LIVE VACCINE;

ADOLESCENT; ARTICLE; ASIA; CHILD; DENGUE; DRUG EFFICACY; HAEMOPHILUS MENINGITIS; HOSPITALIZATION; HUMAN; INCIDENCE; LICENSING; MAJOR CLINICAL STUDY; MORBIDITY; PNEUMOCOCCAL INFECTION; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROTAVIRUS INFECTION; SCHOOL CHILD; SOUTH AND CENTRAL AMERICA; VACCINATION; VIRAL GASTROENTERITIS; STATISTICS AND NUMERICAL DATA;

ASIA; DENGUE; DENGUE VACCINES; HOSPITALIZATION; INCIDENCE; LATIN AMERICA; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VACCINATION; VACCINES, ATTENUATED;

EID: 84962349428     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2016.03.017     Document Type: Article

References (22)

1. Bhatt S., Gething P.W., Brady O.J., Messina J.P., Farlow A.W., Moyes C.L., et al. The global distribution and burden of dengue. Nature 2013, 496:504-507.
2. Wilder-Smith A., Macary P. Dengue: challenges for policy makers and vaccine developers. Curr Infect Dis Rep 2014, 16:404.
3. Capeding M.R., Tran N.H., Hadinegoro S.R., Ismail H.I., Chotpitayasunondh T., Chua M.N., et al. Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. Lancet 2014, 384:1358-1365.
4. Villar L., Dayan G.H., Arredondo-Garcia J.L., Rivera D.M., Cunha R., Deseda C., et al. Efficacy of a tetravalent dengue vaccine in children in Latin America. N Engl J Med 2015, 372:113-123.
5. Hadinegoro S.R., Arredondo-Garcia J.L., Capeding M.R., Deseda C., Chotpitayasunondh T., Dietze R., et al. Efficacy and long-term safety of a dengue vaccine in regions of endemic disease. N Engl J Med 2015, 373(13):1195-1206.
6. Wilder-Smith A., Massad E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines 2016, 1-5.
7. Gessner B.D., Feikin D.R. Vaccine preventable disease incidence as a complement to vaccine efficacy for setting vaccine policy. Vaccine 2014, 32:3133-3138.
8. Kelly H., Attia J., Andrews R., Heller R.F. The number needed to vaccinate (NNV) and population extensions of the NNV: comparison of influenza and pneumococcal vaccine programmes for people aged 65 years and over. Vaccine 2004, 22:2192-2198.
9. Tregnaghi M.W., Saez-Llorens X., Lopez P., Abate H., Smith E., Pósleman A., et al. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: a double-blind randomized controlled trial. PLoS Med 2014, 11:e1001657.
10. Levine O.S., Lagos R., Munoz A., Villaroel J., Alvarez A.M., Levine M.M., et al. Defining the burden of pneumonia in children preventable by vaccination against Haemophilus influenzae type b. Pediatr Infect Dis J 1999, 18:1060-1064.
11. Ruiz-Palacios G.M., Perez-Schael I., Velazquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354:11-22.
12. Feikin D.R., Scott J.A., Gessner B.D. Use of vaccines as probes to define disease burden. Lancet 2014, 383:1762-1770.
13. Gessner B.D., Sutanto A., Linehan M., Djelantik I.G., Fletcher T., Gerudug I.K., et al. Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial. Lancet 2005, 365:43-52.
14. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
15. Munira S.L., Fritzen S.A. What influences government adoption of vaccines in developing countries? A policy process analysis. Soc Sci Med 2007, 65:1751-1764.
16. Madhi S.A., Cunliffe N.A., Steele D., Witte D., Kirsten M., Louw C., et al. Effect of human rotavirus vaccine on severe diarrhea in African infants. N Engl J Med 2010, 362:289-298.
17. Leino T., Ollgren J., Salo H., Tiihonen P., Kilpi T. First year experience of rotavirus immunisation programme in Finland. Vaccine 2012, 31:176-182.
18. Wilder-Smith A., Gubler D.J. PUBLIC HEALTH. Dengue vaccines at a crossroad. Science 2015, 350:626-627.
19. Barnighausen T., Bloom D.E., Cafiero E.T., O'Brien J.C. Valuing the broader benefits of dengue vaccination, with a preliminary application to Brazil. Semin Immunol 2013, 25:104-113.
20. Wilder-Smith A., Massad E. Age specific differences in efficacy and safety for the CYD-tetravalent dengue vaccine. Expert Rev Vaccines 2016, 15(4):437-441.
21. Edelman R., Hombach J. Guidelines for the clinical evaluation of dengue vaccines in endemic areas: summary of a World Health Organization Technical Consultation. Vaccine 2008, 26:4113-4119.
22. Velumani S., Toh Y.X., Balasingam S., Archuleta S., Leo Y.S., Gan V.C., et al. Low antibody titers five years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naive vaccines. Hum Vaccin Immunother 2016.